PARATEK PHARMACEUTICALS INC (PRTK) Stock Price, Quote, News and Overview
NASDAQ:PRTK - Nasdaq - US6993743029 - Common Stock - Currency: USD
PRTK Quote, Performance and Key Statistics
2.23
+0.04 (+1.83%)
The current stock price of PRTK is 2.23 USD. In the past month the price increased by 2.29%. In the past year, price decreased by -2.62%.
PRTK Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About PRTK
Company Profile
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. The company is headquartered in Boston, Massachusetts and currently employs 268 full-time employees. The company went IPO on 2006-05-10. The firm is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. The company markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.
Company Info
PARATEK PHARMACEUTICALS INC
75 Park Plaza, 4th Floor
Boston MASSACHUSETTS 02116 US
CEO: Evan Loh
Employees: 268
Company Website: https://www.paratekpharma.com/
Phone: 16178076600.0
PARATEK PHARMACEUTICALS INC / PRTK FAQ
What is the stock price of PARATEK PHARMACEUTICALS INC today?
The current stock price of PRTK is 2.23 USD. The price increased by 1.83% in the last trading session.
What is the ticker symbol for PARATEK PHARMACEUTICALS INC stock?
The exchange symbol of PARATEK PHARMACEUTICALS INC is PRTK and it is listed on the Nasdaq exchange.
On which exchange is PRTK stock listed?
PRTK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PARATEK PHARMACEUTICALS INC stock?
9 analysts have analysed PRTK and the average price target is 3.16 USD. This implies a price increase of 41.79% is expected in the next year compared to the current price of 2.23. Check the PARATEK PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PARATEK PHARMACEUTICALS INC worth?
PARATEK PHARMACEUTICALS INC (PRTK) has a market capitalization of 127.82M USD. This makes PRTK a Micro Cap stock.
How many employees does PARATEK PHARMACEUTICALS INC have?
PARATEK PHARMACEUTICALS INC (PRTK) currently has 268 employees.
What are the support and resistance levels for PARATEK PHARMACEUTICALS INC (PRTK) stock?
PARATEK PHARMACEUTICALS INC (PRTK) has a support level at 2.21 and a resistance level at 2.24. Check the full technical report for a detailed analysis of PRTK support and resistance levels.
Is PARATEK PHARMACEUTICALS INC (PRTK) expected to grow?
The Revenue of PARATEK PHARMACEUTICALS INC (PRTK) is expected to grow by 9.93% in the next year. Check the estimates tab for more information on the PRTK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PARATEK PHARMACEUTICALS INC (PRTK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRTK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRTK, evaluating the profitability, health, valuation and growth aspects
- PARATEK PHARMACEUTICALS INC (PRTK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PARATEK PHARMACEUTICALS INC (PRTK) Sales and EPS estimates to see what analysts future expectations are.
- PARATEK PHARMACEUTICALS INC (PRTK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PARATEK PHARMACEUTICALS INC (PRTK) Insider and Institutional Ownership to learn about the owners and their transactions.
- PARATEK PHARMACEUTICALS INC (PRTK) Stock Chart to make your own analysis
- PARATEK PHARMACEUTICALS INC (PRTK) Latest news and press-releases to stay up to date.
Does PARATEK PHARMACEUTICALS INC (PRTK) stock pay dividends?
PRTK does not pay a dividend.
When does PARATEK PHARMACEUTICALS INC (PRTK) report earnings?
PARATEK PHARMACEUTICALS INC (PRTK) will report earnings on 2023-11-01, before the market open.
What is the Price/Earnings (PE) ratio of PARATEK PHARMACEUTICALS INC (PRTK)?
PARATEK PHARMACEUTICALS INC (PRTK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.1).
PRTK Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PRTK. When comparing the yearly performance of all stocks, PRTK turns out to be only a medium performer in the overall market: it outperformed 48.22% of all stocks.
PRTK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRTK. PRTK has a bad profitability rating. Also its financial health evaluation is rather negative.
PRTK Financial Highlights
Over the last trailing twelve months PRTK reported a non-GAAP Earnings per Share(EPS) of -1.1. The EPS increased by 35.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PRTK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to PRTK. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 32.14% and a revenue growth 9.93% for PRTK